William Blair Has Bearish Forecast for BMY FY2026 Earnings
Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...
Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
Model Portfolio For Capital Appreciation, February 2025
Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.
Bristol-Myers Squibb (BMY) Gets a Hold from Citi
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...
Stock market today: S&P 500, Nasdaq pop with Amazon set to highlight earnings rush
US stocks were mixed on Thursday in anticipation of Amazon's quarterly results, as investors assessed the earnings season so ...
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years”
We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.
Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
Research Analysts Issue Forecasts for BMY FY2024 Earnings
Analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Tuesday, February 4th. Cantor Fitzgerald analyst O.
Is Bristol-Myers Squibb Company (BMY) the Best Wide Moat Stock to Invest In?
To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...
Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Jefferies analyst Akash Tewari maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) on February 3 and set a price target of ...